SGLT2 inhibitors: how do they affect the cardiac cells

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were first approved for type 2 diabetes.
• SGLT2Is promote glucose excretion via the kidneys, distinct from insulin-based therapies.
• Their therapeutic applications have expanded beyond diabetes to heart failure and chronic kidney disease.

Purpose of the Study:

• To review the diverse effects of SGLT2Is on cardiac cells.
• To elucidate the mechanisms underlying the beneficial cardiac effects of SGLT2Is.

Main Methods:

• Review of preclinical and clinical studies on SGLT2 inhibitors.
• Analysis of proposed mechanisms for SGLT2Is' cardiovascular benefits.

Main Results:

• SGLT2Is demonstrate protective effects on cardiac cells.
• Mechanisms include inhibition of fibrosis, hypertrophy, apoptosis, inflammation, and oxidative stress.
• SGLT2Is regulate mitochondrial function, ion transport, and stimulate autophagy.

Conclusions:

• SGLT2Is are now recognized for their significant role in managing heart failure and chronic kidney disease, irrespective of diabetes status.
• The cardioprotective effects of SGLT2Is are mediated by multiple cellular and molecular pathways.
• Further understanding of these mechanisms can optimize SGLT2I therapy for cardiovascular conditions.